Janus Henderson Group PLC Schedule 13G passive stakes

Janus Henderson Group plc has filed an Amendment No. 5 to its Schedule 13G, reporting a beneficial ownership of 7.2% in Ascendis Pharma A/S as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, reporting a beneficial ownership of 0.0% in Perspective Therapeutics Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 0.0% beneficial ownership stake in Applied Therapeutics Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a 1.6% beneficial ownership stake in PepGen Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a 3.0% beneficial ownership stake in Immunic, Inc. as of December 31, 2024, held for investment purposes in the ordinary course of business.

Janus Henderson Group PLC has filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.3% in Caesars Entertainment Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, indicating it holds no beneficial ownership in Precision BioSciences, Inc. as of December 31, 2024.

Janus Henderson Group PLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 4.8% in NeoGenomics Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 4.9% in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed an amended Schedule 13G, disclosing that it no longer holds any beneficial ownership in Neurogene Inc., effectively divesting its entire stake.

Janus Henderson Group plc has filed an amended Schedule 13G indicating it no longer holds any beneficial ownership in CytomX Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed beneficial ownership of 5.6% of Entrada Therapeutics, Inc.'s common stock as of December 31, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a 10.0% beneficial ownership stake in Forte Biosciences, Inc. as of December 31, 2024.

Janus Henderson Group plc has disclosed a 5.2% beneficial ownership stake in Revolution Medicines, Inc., held for investment purposes in the ordinary course of business.

Janus Henderson Group PLC has filed a Schedule 13G, revealing a significant passive ownership stake of 5.3% in Edgewise Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed a Schedule 13G, reporting a 5.9% beneficial ownership stake in Avidity Biosciences, Inc. as of December 31, 2024.

Janus Henderson Group plc has filed a Schedule 13G, reporting a passive beneficial ownership of 6.1% of the common stock of JANUX THERAPEUTICS, INC.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed passive beneficial ownership stakes of 6.6% and 6.0% respectively, in Protara Therapeutics, Inc. common stock as of December 31, 2024.

Capital Research Global Investors has filed an amended Schedule 13G, revealing a 4.5% beneficial ownership stake in Janus Henderson Group PLC as of an event date of September 30, 2024.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have reported beneficial ownership of 11.6% of Bright Minds Biosciences Inc.'s common stock.

Janus Henderson Group plc, along with its subsidiary Janus Henderson Biotech Innovation Master Fund Ltd, has filed an amended Schedule 13G disclosing a combined beneficial ownership of 15.2% in 89bio, Inc.'s common stock.

Janus Henderson Group PLC and its subsidiary, Janus Henderson Contrarian Fund, have filed an amended Schedule 13G, revealing a combined beneficial ownership of 8.8% in The Beauty Health Company's common stock.

Janus Henderson Group plc has filed a Schedule 13G, revealing a beneficial ownership of 9.5% of Surgery Partners, Inc.'s common stock, held for investment purposes.

Janus Henderson Group PLC and its affiliated entities have reported a combined beneficial ownership of 10.1% in Larimar Therapeutics, Inc. as of December 31, 2024.

Janus Henderson Group plc and its affiliate have filed an amended Schedule 13G, reporting a combined beneficial ownership of 1,046,899 shares, or 17.2%, of Monopar Therapeutics Inc.'s common stock as of December 31, 2024.